Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #LB-208: Histone deacetylase (HDAC) 3 inhibiton through LBH589 dephosphorylate Akt through protein phosphatase 1 (PP1) complexes in diffuse large B cell Lymphoma

Mamta Gupta, Anne Novak, Stephen Ansell and Thomas Witzig
Mamta Gupta
Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Novak
Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Ansell
Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Witzig
Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL) that is considered curable; however, even with rituximab-based chemoimmunotherapy 40% relapse and die of disease. New agents with novel mechanisms of action are needed for this disease. We have demonstrated that treatment of DLBCL cells with the histone deacetylase (HDAC) inhibitor LBH589 as a single agent induced growth inhibition at nano-molar doses in association with inhibition of constitutively activated Akt in a time and dose dependent manner. The aim of the present study is to explore the mechanism by which LBH causes Akt deactivation in DLBCL. Mechanistically, this Akt dephosphorylation might be mediated through the deactivation of upstream kinases or the activation of a downstream phosphatase. To discern the role of transcriptional activation by LBH, we assessed the expression levels of a series of signaling proteins related to the regulation of Akt signaling pathways in LBH treated DLBCL cell line DHL-6. Proteins investigated included the p85 regulatory subunits of PI3K, PDK-1, Akt, PP1, and PP2A. We have shown that LBH exposure did not alter the expression level of any of these signaling proteins, excluding the involvement of transcriptional activation in altering the status of Akt phosphorylation. Consequently, we investigated a potential link between LBH-mediated Akt down-regulation and protein phosphatase activation by examining the effect of the PP1 inhibitor calyculin A on phospho-Akt levels in LBH-treated DHL-6 cells. Calyculin A completely abrogated the effect of LBH on phospho-Akt, suggesting the involvement of PP1 in LBH-facilitated Akt dephosphorylation. Next we investigated whether LBH causes PP1-mediated Akt dephosphorylation through HDAC inhibition. Since LBH treatment did not lead to increased PP1 levels, we hypothesized that the HDAC inhibitor might cause disruption of HDAC-PP1complexes, which would free PP1 to interact with Akt. LBH treatment produced disruption of the HDAC-PP1 complex accompanied by a dose dependent increase in PP1-Akt associations. We also found that DLBCL lines expressed both class I and class II HDACs and LBH treatment significantly inhibited HDAC3 and HDAC4 expression, while had only moderate effects on other HDACs. Further, we used HDAC3 and HDAC4 specific siRNAs to selectively knock down the expression of HDACs 3 and 4 and found that repressed expression of HDAC3 but not HDAC4 led to decreased Akt phosphorylation. In summary, the above findings suggest that LBH causes PP1-mediated Akt dephosphorylation by sequestering HDAC 3. This novel HDAC-PP1-Akt mechanism will allow the design of more effective strategies to optimize the use of these agents in DLBCL as single-agents or in combination with other drugs.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-208.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #LB-208: Histone deacetylase (HDAC) 3 inhibiton through LBH589 dephosphorylate Akt through protein phosphatase 1 (PP1) complexes in diffuse large B cell Lymphoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #LB-208: Histone deacetylase (HDAC) 3 inhibiton through LBH589 dephosphorylate Akt through protein phosphatase 1 (PP1) complexes in diffuse large B cell Lymphoma
Mamta Gupta, Anne Novak, Stephen Ansell and Thomas Witzig
Cancer Res May 1 2009 (69) (9 Supplement) LB-208;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #LB-208: Histone deacetylase (HDAC) 3 inhibiton through LBH589 dephosphorylate Akt through protein phosphatase 1 (PP1) complexes in diffuse large B cell Lymphoma
Mamta Gupta, Anne Novak, Stephen Ansell and Thomas Witzig
Cancer Res May 1 2009 (69) (9 Supplement) LB-208;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

HDAC and Methyltransferase Inhibitors -- Poster Presentations - Late-Breaking Abstracts

  • Abstract #LB-207: The antitumor effects of OSU-HDAC42, a histone deacetylase inhibitor, in HER2-positive breast cancer are mediated partly through Hsp90 modulation
  • Abstract #LB-209: The HDAC inhibitor belinostat downregulates survivin in the FET colon cancer cell line by a TGF\#946; signaling dependent mechanism
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement